These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32490341)

  • 1. Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers.
    Hoshino I; Nabeya Y; Takiguchi N; Gunji H; Ishige F; Iwatate Y; Shiratori F; Yajima S; Okada R; Shimada H
    Ann Gastroenterol Surg; 2020 May; 4(3):275-282. PubMed ID: 32490341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
    Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
    J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study.
    Okada R; Otsuka Y; Yokosuka O; Kato N; Imazaki F; Hoshino I; Sugiura N; Mizumoto H; Azemoto R; Kato K; Shimada H
    Oncol Lett; 2022 Oct; 24(4):367. PubMed ID: 36238856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer.
    Kawada J; Saito T; Kurokawa Y; Kawabata R; Takeno A; Takeoka T; Nose Y; Wada H; Eguchi H; Doki Y;
    Ann Gastroenterol Surg; 2024 Mar; 8(2):243-250. PubMed ID: 38455491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
    Dong J; Zeng BH; Xu LH; Wang JY; Li MZ; Zeng MS; Liu WL
    J Transl Med; 2010 Sep; 8():81. PubMed ID: 20813067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer.
    Long YY; Wang Y; Huang QR; Zheng GS; Jiao SC
    Exp Ther Med; 2014 Oct; 8(4):1279-1284. PubMed ID: 25187840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers.
    Nanami T; Hoshino I; Shiratori F; Yajima S; Oshima Y; Suzuki T; Ito M; Hiwasa T; Kuwajima A; Shimada H
    Int J Clin Oncol; 2022 Jan; 27(1):72-76. PubMed ID: 34632560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
    Nagata Y; Kageyama S; Ishikawa T; Kokura S; Okayama T; Abe T; Murakami M; Otsuka K; Ariyoshi T; Kojima T; Taniguchi K; Kobayashi S; Shimada H; Yajima S; Suzuki T; Hirano S; Tsuchikawa T; Shichinohe T; Ueda S; Kanetaka K; Yoneda A; Wada H; Doki Y; Yamaue H; Katsuda M; Ohi M; Yasuda H; Kondo K; Kataoka M; Kodera Y; Koike M; Shiraishi T; Miyahara Y; Goshima N; Fukuda E; Yamaguchi K; Sato E; Ikeda H; Yamada T; Osako M; Hirai K; Miyamoto H; Watanabe T; Shiku H
    Cancer Immunol Immunother; 2022 Nov; 71(11):2743-2755. PubMed ID: 35429246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritherapeutic Serum p53 Antibody Titers are Predictors of Survival in Patients with Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemotherapy and Surgery.
    Yamashita K; Makino T; Tanaka K; Yamasaki M; Yamamoto M; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    World J Surg; 2017 Jun; 41(6):1566-1574. PubMed ID: 28108772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma.
    Bujas T; Marusic Z; Peric Balja M; Mijic A; Kruslin B; Tomas D
    Eur J Histochem; 2011 Mar; 55(1):e7. PubMed ID: 21556122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: A prospective multicenter study.
    Okada R; Otsuka Y; Wakabayashi T; Shinoda M; Aoki T; Murakami M; Arizumi S; Yamamoto M; Aramaki O; Takayama T; Wakiyama S; Yanaga K; Amikura K; Kaneko H; Shimada H
    Int J Cancer; 2020 Nov; 147(9):2578-2586. PubMed ID: 32574375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study.
    Wang YX; Li FL; Du LX; Liu JF; Huo LG; Li SQ; Tian B
    Cancer Manag Res; 2021; 13():6123-6128. PubMed ID: 34377031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.
    Saito T; Kurokawa Y; Fujitani K; Kawabata R; Takeno A; Mikami J; Endo S; Matsuyama J; Akamaru Y; Hirota M; Kishi K; Urakawa S; Yamamoto K; Tanaka K; Takahashi T; Oka M; Wada H; Eguchi H; Doki Y
    Br J Cancer; 2024 Apr; 130(7):1157-1165. PubMed ID: 38326601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery.
    Oshima Y; Suzuki T; Yajima S; Nanami T; Shiratori F; Funahashi K; Shimada H
    Surg Today; 2020 Nov; 50(11):1402-1408. PubMed ID: 32458231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma.
    Suzuki T; Yajima S; Ishioka N; Nanami T; Oshima Y; Washizawa N; Funahashi K; Otsuka S; Nemoto T; Shimada H
    Esophagus; 2018 Oct; 15(4):294-300. PubMed ID: 29959634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma].
    Zhang WM; Xiao G; Xie D; Zhang M; Guo AL; Wen JM
    Ai Zheng; 2005 May; 24(5):622-6. PubMed ID: 15890110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.